BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 31919076)

  • 1. WEE1 inhibition induces glutamine addiction in T-cell acute lymphoblastic leukemia.
    Hu J; Wang T; Xu J; Wu S; Wang L; Su H; Jiang J; Yue M; Wang J; Wang D; Li P; Zhou F; Liu Y; Qing G; Liu H
    Haematologica; 2021 Jul; 106(7):1816-1827. PubMed ID: 31919076
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting WEE1 to enhance conventional therapies for acute lymphoblastic leukemia.
    Ghelli Luserna Di Rorà A; Beeharry N; Imbrogno E; Ferrari A; Robustelli V; Righi S; Sabattini E; Verga Falzacappa MV; Ronchini C; Testoni N; Baldazzi C; Papayannidis C; Abbenante MC; Marconi G; Paolini S; Parisi S; Sartor C; Fontana MC; De Matteis S; Iacobucci I; Pelicci PG; Cavo M; Yen TJ; Martinelli G
    J Hematol Oncol; 2018 Aug; 11(1):99. PubMed ID: 30068368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bortezomib Is Effective in the Treatment of T Lymphoblastic Leukaemia by Inducing DNA Damage, WEE1 Downregulation, and Mitotic Catastrophe.
    Din RU; Jiao A; Qiu Y; Mohan AAM; Yuen KC; Wong HT; Wan TM; Wong PO; Sin CF
    Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37834095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined inhibition of Chk1 and Wee1 as a new therapeutic strategy for mantle cell lymphoma.
    Chilà R; Basana A; Lupi M; Guffanti F; Gaudio E; Rinaldi A; Cascione L; Restelli V; Tarantelli C; Bertoni F; Damia G; Carrassa L
    Oncotarget; 2015 Feb; 6(5):3394-408. PubMed ID: 25428911
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased activity of both CDK1 and CDK2 is necessary for the combinatorial activity of WEE1 inhibition and cytarabine.
    Garcia TB; Fosmire SP; Porter CC
    Leuk Res; 2018 Jan; 64():30-33. PubMed ID: 29175378
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CHK1 and WEE1 inhibition combine synergistically to enhance therapeutic efficacy in acute myeloid leukemia ex vivo.
    Chaudhuri L; Vincelette ND; Koh BD; Naylor RM; Flatten KS; Peterson KL; McNally A; Gojo I; Karp JE; Mesa RA; Sproat LO; Bogenberger JM; Kaufmann SH; Tibes R
    Haematologica; 2014 Apr; 99(4):688-96. PubMed ID: 24179152
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MicroRNA-497 increases apoptosis in MYCN amplified neuroblastoma cells by targeting the key cell cycle regulator WEE1.
    Creevey L; Ryan J; Harvey H; Bray IM; Meehan M; Khan AR; Stallings RL
    Mol Cancer; 2013 Mar; 12():23. PubMed ID: 23531080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic inhibition of the atypical kinase Wee1 selectively drives apoptosis of p53 inactive tumor cells.
    Pappano WN; Zhang Q; Tucker LA; Tse C; Wang J
    BMC Cancer; 2014 Jun; 14():430. PubMed ID: 24927813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined inhibition of Chk1 and Wee1: in vitro synergistic effect translates to tumor growth inhibition in vivo.
    Carrassa L; Chilà R; Lupi M; Ricci F; Celenza C; Mazzoletti M; Broggini M; Damia G
    Cell Cycle; 2012 Jul; 11(13):2507-17. PubMed ID: 22713237
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint.
    Lin X; Chen D; Zhang C; Zhang X; Li Z; Dong B; Gao J; Shen L
    J Exp Clin Cancer Res; 2018 Jun; 37(1):129. PubMed ID: 29954437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic targeting of CHK1 and mTOR in MYC-driven tumors.
    Song X; Wang L; Wang T; Hu J; Wang J; Tu R; Su H; Jiang J; Qing G; Liu H
    Carcinogenesis; 2021 Apr; 42(3):448-460. PubMed ID: 33206174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. WEE1 inhibition sensitizes osteosarcoma to radiotherapy.
    PosthumaDeBoer J; Würdinger T; Graat HC; van Beusechem VW; Helder MN; van Royen BJ; Kaspers GJ
    BMC Cancer; 2011 Apr; 11():156. PubMed ID: 21529352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined inhibition of the cell cycle related proteins Wee1 and Chk1/2 induces synergistic anti-cancer effect in melanoma.
    Magnussen GI; Emilsen E; Giller Fleten K; Engesæter B; Nähse-Kumpf V; Fjær R; Slipicevic A; Flørenes VA
    BMC Cancer; 2015 Jun; 15():462. PubMed ID: 26054341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergism Through WEE1 and CHK1 Inhibition in Acute Lymphoblastic Leukemia.
    Ghelli Luserna Di Rorà A; Bocconcelli M; Ferrari A; Terragna C; Bruno S; Imbrogno E; Beeharry N; Robustelli V; Ghetti M; Napolitano R; Chirumbolo G; Marconi G; Papayannidis C; Paolini S; Sartor C; Simonetti G; Yen TJ; Martinelli G
    Cancers (Basel); 2019 Oct; 11(11):. PubMed ID: 31717700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of Wee1 sensitizes cancer cells to antimetabolite chemotherapeutics in vitro and in vivo, independent of p53 functionality.
    Van Linden AA; Baturin D; Ford JB; Fosmire SP; Gardner L; Korch C; Reigan P; Porter CC
    Mol Cancer Ther; 2013 Dec; 12(12):2675-84. PubMed ID: 24121103
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of mitochondrial complex I reverses NOTCH1-driven metabolic reprogramming in T-cell acute lymphoblastic leukemia.
    Baran N; Lodi A; Dhungana Y; Herbrich S; Collins M; Sweeney S; Pandey R; Skwarska A; Patel S; Tremblay M; Kuruvilla VM; Cavazos A; Kaplan M; Warmoes MO; Veiga DT; Furudate K; Rojas-Sutterin S; Haman A; Gareau Y; Marinier A; Ma H; Harutyunyan K; Daher M; Garcia LM; Al-Atrash G; Piya S; Ruvolo V; Yang W; Shanmugavelandy SS; Feng N; Gay J; Du D; Yang JJ; Hoff FW; Kaminski M; Tomczak K; Eric Davis R; Herranz D; Ferrando A; Jabbour EJ; Emilia Di Francesco M; Teachey DT; Horton TM; Kornblau S; Rezvani K; Sauvageau G; Gagea M; Andreeff M; Takahashi K; Marszalek JR; Lorenzi PL; Yu J; Tiziani S; Hoang T; Konopleva M
    Nat Commun; 2022 May; 13(1):2801. PubMed ID: 35589701
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A regimen combining the Wee1 inhibitor AZD1775 with HDAC inhibitors targets human acute myeloid leukemia cells harboring various genetic mutations.
    Zhou L; Zhang Y; Chen S; Kmieciak M; Leng Y; Lin H; Rizzo KA; Dumur CI; Ferreira-Gonzalez A; Dai Y; Grant S
    Leukemia; 2015 Apr; 29(4):807-18. PubMed ID: 25283841
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transcriptional repression of WEE1 by Kruppel-like factor 2 is involved in DNA damage-induced apoptosis.
    Wang F; Zhu Y; Huang Y; McAvoy S; Johnson WB; Cheung TH; Chung TK; Lo KW; Yim SF; Yu MM; Ngan HY; Wong YF; Smith DI
    Oncogene; 2005 Jun; 24(24):3875-85. PubMed ID: 15735666
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sequential combination of bortezomib and WEE1 inhibitor, MK-1775, induced apoptosis in multiple myeloma cell lines.
    Barbosa RSS; Dantonio PM; Guimarães T; de Oliveira MB; Fook Alves VL; Sandes AF; Fernando RC; Colleoni GWB
    Biochem Biophys Res Commun; 2019 Nov; 519(3):597-604. PubMed ID: 31540690
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulation of cell cycle checkpoint kinase WEE1 by miR-195 in malignant melanoma.
    Bhattacharya A; Schmitz U; Wolkenhauer O; Schönherr M; Raatz Y; Kunz M
    Oncogene; 2013 Jun; 32(26):3175-83. PubMed ID: 22847610
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.